126 related articles for article (PubMed ID: 15369136)
1. A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay.
Harada H; Saijo K; Ishiwata I; Ohno T
Hum Cell; 2004 Mar; 17(1):43-8. PubMed ID: 15369136
[TBL] [Abstract][Full Text] [Related]
2. [Selective expansion of human natural killer cells].
Peng BG; Liang LJ; He Q; Li J; Lu MD
Ai Zheng; 2005 Oct; 24(10):1287-9. PubMed ID: 16219151
[TBL] [Abstract][Full Text] [Related]
3. A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells.
Harada H; Watanabe S; Saijo K; Ishiwata I; Ohno T
Exp Hematol; 2004 Jul; 32(7):614-21. PubMed ID: 15246157
[TBL] [Abstract][Full Text] [Related]
4. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT.
Harada H; Saijo K; Watanabe S; Tsuboi K; Nose T; Ishiwata I; Ohno T
Jpn J Cancer Res; 2002 Mar; 93(3):313-9. PubMed ID: 11927014
[TBL] [Abstract][Full Text] [Related]
5. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.
Peng BG; Liang LJ; He Q; Huang JF; Lu MD
World J Gastroenterol; 2004 Jul; 10(14):2119-23. PubMed ID: 15237448
[TBL] [Abstract][Full Text] [Related]
6. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.
Kim GG; Donnenberg VS; Donnenberg AD; Gooding W; Whiteside TL
J Immunol Methods; 2007 Aug; 325(1-2):51-66. PubMed ID: 17617419
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets.
Zhu HG; Zollner TM; Klein-Franke A; Anderer FA
J Cancer Res Clin Oncol; 1994; 120(7):383-8. PubMed ID: 7514604
[TBL] [Abstract][Full Text] [Related]
8. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
9. Enzyme release assay of human NK cell activity using beta-galactosidase-expressing K562 target cell line.
Ohmori H; Ikeda H; Tanigawa T; Takai T; Hikida M
J Immunol Methods; 1993 Aug; 164(1):131-5. PubMed ID: 8360503
[TBL] [Abstract][Full Text] [Related]
10. A novel enhanced green fluorescent protein (EGFP)-K562 flow cytometric method for measuring natural killer (NK) cell cytotoxic activity.
Kantakamalakul W; Jaroenpool J; Pattanapanyasat K
J Immunol Methods; 2003 Jan; 272(1-2):189-97. PubMed ID: 12505723
[TBL] [Abstract][Full Text] [Related]
11. Direct visualisation and quantification of cellular cytotoxicity using two colour flourescence.
Kroesen BJ; Mesander G; ter Haar JG; The TH; de Leij L
J Immunol Methods; 1992 Nov; 156(1):47-54. PubMed ID: 1431162
[TBL] [Abstract][Full Text] [Related]
12. Super-sensitive epithelial cell line and colorimetric assay to replace the conventional K562 target and chromium release assay for assessment of non-MHC-restricted cytotoxicity.
Nouri AM; Mansouri M; Hussain RF; Dos Santos AV; Oliver RT
J Immunol Methods; 1995 Mar; 180(1):63-8. PubMed ID: 7534804
[TBL] [Abstract][Full Text] [Related]
13. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
14. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
15. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
16. Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells.
Shresta S; MacIvor DM; Heusel JW; Russell JH; Ley TJ
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5679-83. PubMed ID: 7777569
[TBL] [Abstract][Full Text] [Related]
17. Factors determining the ability of cytokine-activated killer cells to lyse human ovarian carcinoma targets.
Hirte HW; Clark DA
Cell Immunol; 1991 Aug; 136(1):122-32. PubMed ID: 2060017
[TBL] [Abstract][Full Text] [Related]
18. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
19. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A.
Jiang YZ; Couriel D; Mavroudis DA; Lewalle P; Malkovska V; Hensel NF; Dermime S; Molldrem J; Barrett AJ
Immunology; 1996 Mar; 87(3):481-6. PubMed ID: 8778037
[TBL] [Abstract][Full Text] [Related]
20. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
